UniProt P27448 · PDB · AlphaFold · Substrate: CHKtide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 97.4% | 2.6% | 78.64 | 0.500 |
| 2 | Brigatinib | 90.3% | 9.7% | 82.96 | 0.513 |
| 3 | Defactinib | 80.5% | 19.5% | 92.68 | 0.450 |
| 4 | Baricitinib | 67.2% | 32.9% | 97.99 | 0.616 |
| 5 | Sunitinib | 66.0% | 34.0% | 91.73 | 0.524 |
| 6 | Upadacitinib | 60.1% | 39.9% | 97.98 | 0.663 |
| 7 | Repotrectinib | 59.5% | 40.5% | 84.21 | 0.608 |
| 8 | Axitinib | 52.9% | 47.1% | 93.23 | 0.688 |
| 9 | Bosutinib | 36.6% | 63.4% | 87.22 | 0.555 |
| 10 | Fedratinib | 36.4% | 63.6% | 96.21 | 0.576 |
| 11 | Pemigatinib | 35.5% | 64.5% | 98.23 | 0.718 |
| 12 | Rabusertib | 33.8% | 66.2% | 98.74 | 0.687 |
| 13 | Ruxolitinib | 31.3% | 68.7% | 98.25 | 0.592 |
| 14 | Crizotinib | 30.8% | 69.2% | 91.39 | 0.581 |
| 15 | Selpercatinib | 22.5% | 77.5% | 96.72 | 0.635 |
| 16 | Neratinib | 20.4% | 79.6% | 93.18 | 0.597 |
| 17 | Abrocitinib | 17.5% | 82.5% | 99.50 | 0.581 |
| 18 | Abemaciclib | 17.3% | 82.7% | 91.48 | 0.563 |
| 19 | Nintedanib | 16.8% | 83.2% | 90.23 | 0.608 |
| 20 | Pacritinib | 16.5% | 83.5% | 88.64 | 0.452 |
Paralog block
MARK1, MARK2_PAR_1BA, MARK3, MARK4
EMT expression
- Mesenchymal log2(TPM+1): 5.57
- Epithelial log2(TPM+1): 5.32
- Fold change: 0.25
- Status: No significant change
Selectivity landscape vs inhibition on MARK3
Each point is one of the 92 approved drugs; color = inhibition % on MARK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…